301230 泓博医药
午间休市 11-06 11:30:00
资讯
新帖
简况
泓博医药（301230）11月5日主力资金净卖出2386.60万元
证券之星 · 09:05
泓博医药（301230）11月5日主力资金净卖出2386.60万元
泓博医药(301230)10月30日股东户数2.77万户，较上期减少10.16%
证券之星 · 11-04 19:42
泓博医药(301230)10月30日股东户数2.77万户，较上期减少10.16%
11月4日泓博医药涨7.51%，益民红利成长混合基金重仓该股
证券之星 · 11-04 17:53
11月4日泓博医药涨7.51%，益民红利成长混合基金重仓该股
泓博医药：截至2026年10月30日股东户数为27,687户
证券之星 · 11-04 15:45
泓博医药：截至2026年10月30日股东户数为27,687户
泓博医药（301230）11月3日主力资金净卖出301.10万元
证券之星 · 11-04 09:59
泓博医药（301230）11月3日主力资金净卖出301.10万元
11月3日泓博医药跌7.89%，益民红利成长混合基金重仓该股
证券之星 · 11-03 17:24
11月3日泓博医药跌7.89%，益民红利成长混合基金重仓该股
股市必读：泓博医药(301230)股东户数3.08万户，较上期增加18.7%
证券之星 · 11-02
股市必读：泓博医药(301230)股东户数3.08万户，较上期增加18.7%
泓博医药(301230)10月20日股东户数3.08万户，较上期增加18.7%
证券之星 · 10-30
泓博医药(301230)10月20日股东户数3.08万户，较上期增加18.7%
泓博医药：公司将充分发挥上游药物发现及工艺开发业务的项目导流优势
证券之星 · 10-30
泓博医药：公司将充分发挥上游药物发现及工艺开发业务的项目导流优势
泓博医药：截至2026年10月20日股东户数为30,818户
证券之星 · 10-30
泓博医药：截至2026年10月20日股东户数为30,818户
泓博医药：发挥协同优势打通全链条转化能力
证券之星 · 10-29
泓博医药：发挥协同优势打通全链条转化能力
泓博医药（301230）10月28日主力资金净卖出1272.13万元
证券之星 · 10-29
泓博医药（301230）10月28日主力资金净卖出1272.13万元
10月27日泓博医药跌5.26%，益民红利成长混合基金重仓该股
证券之星 · 10-27
10月27日泓博医药跌5.26%，益民红利成长混合基金重仓该股
泓博医药（301230）10月26日主力资金净卖出9133.30万元
证券之星 · 10-27
泓博医药（301230）10月26日主力资金净卖出9133.30万元
泓博医药（301230）2026年三季报简析：增收不增利，公司应收账款体量较大
证券之星 · 10-24
泓博医药（301230）2026年三季报简析：增收不增利，公司应收账款体量较大
泓博医药（301230）披露2026年三季度报告，10月22日股价下跌6.77%
证券之星 · 10-22
泓博医药（301230）披露2026年三季度报告，10月22日股价下跌6.77%
泓博医药：第四届董事会第十次会议决议公告
证券日报网 · 10-22
泓博医药：第四届董事会第十次会议决议公告
10月22日泓博医药跌6.77%，长城消费增值混合A基金重仓该股
证券之星 · 10-22
10月22日泓博医药跌6.77%，长城消费增值混合A基金重仓该股
10月19日泓博医药跌6.84%，长城消费增值混合A基金重仓该股
证券之星 · 10-19
10月19日泓博医药跌6.84%，长城消费增值混合A基金重仓该股
泓博医药（301230）10月16日主力资金净买入3.16亿元
证券之星 · 10-19
泓博医药（301230）10月16日主力资金净买入3.16亿元
加载更多
公司概况
公司名称：
上海泓博智源医药股份有限公司
所属行业：
研究和试验发展
上市日期：
2022-11-01
主营业务：
上海泓博智源医药股份有限公司的主营业务是药物发现、制药工艺的研究开发以及原料药中间体的商业化生产。公司的主要产品是药物发现（CRO）、工艺研究与开发（CRO/CDMO）、商业化生产（含CMO）。
发行价格：
40.00
{"stockData":{"symbol":"301230","market":"SZ","secType":"STK","nameCN":"泓博医药","latestPrice":30.96,"timestamp":1793939145000,"preClose":32.85,"halted":0,"volume":13128411,"delay":0,"changeRate":-0.0575,"floatShares":163000000,"shares":181000000,"eps":0.1581,"marketStatus":"午间休市","change":-1.89,"latestTime":"11-06 11:30:00","open":31.68,"high":32.68,"low":30.81,"amount":412000000,"amplitude":0.0569,"askPrice":30.96,"askSize":6,"bidPrice":30.95,"bidSize":24,"shortable":0,"etf":0,"ttmEps":0.1581,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793941200000},"marketStatusCode":3,"adr":0,"adjPreClose":32.85,"symbolType":"stock","openAndCloseTimeList":[[1793928600000,1793935800000],[1793941200000,1793948400000]],"highLimit":36.14,"lowLimit":29.57,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":180941126,"isCdr":false,"pbRate":5.86,"roa":"--","peRate":195.825427,"roe":"2.85%","epsLYR":0.25,"committee":0.686411,"marketValue":5602000000,"turnoverRate":0.0807,"status":1,"floatMarketCap":5039000000},"requestUrl":"/m/hq/s/301230","defaultTab":"news","newsList":[{"id":"2681190882","title":"泓博医药（301230）11月5日主力资金净卖出2386.60万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681190882","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681190882?lang=zh_cn&edition=full","pubTime":"2026-11-06 09:05","pubTimestamp":1793927123,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月5日收盘，泓博医药报收于32.85元，上涨7.25%，换手率15.36%，成交量25.0万手，成交额8.11亿元。11月5日的资金流向数据方面，主力资金净流出2386.6万元，占总成交额2.94%，游资资金净流出5493.77万元，占总成交额6.77%，散户资金净流入7880.37万元，占总成交额9.71%。融券方面，融券卖出0.0股，融券偿还200.0股，融券余量1.26万股，融券余额41.36万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600009321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680058735","title":"泓博医药(301230)10月30日股东户数2.77万户，较上期减少10.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680058735","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680058735?lang=zh_cn&edition=full","pubTime":"2026-11-04 19:42","pubTimestamp":1793792562,"startTime":"0","endTime":"0","summary":"证券之星消息，近日泓博医药披露，截至2026年10月30日公司股东户数为2.77万户，较10月20日减少3131.0户，减幅为10.16%。在医疗服务行业个股中，泓博医药股东户数低于行业平均水平，截至10月30日，医疗服务行业平均股东户数为5.0万户。从股价来看，2026年10月20日至2026年10月30日，泓博医药区间跌幅为16.29%，在此期间股东户数减少3131.0户，减幅为10.16%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400036498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680031675","title":"11月4日泓博医药涨7.51%，益民红利成长混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680031675","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680031675?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:53","pubTimestamp":1793785990,"startTime":"0","endTime":"0","summary":"证券之星消息，11月4日泓博医药涨7.51%，收盘报30.63元，换手率13.61%，成交量22.15万手，成交额6.45亿元。重仓泓博医药的公募基金请见下表：根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为益民基金的益民红利成长混合。益民红利成长混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400033255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680080156","title":"泓博医药：截至2026年10月30日股东户数为27,687户","url":"https://stock-news.laohu8.com/highlight/detail?id=2680080156","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680080156?lang=zh_cn&edition=full","pubTime":"2026-11-04 15:45","pubTimestamp":1793778310,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)11月04日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好！请问截止2026年10月 30日公司的股东人数是多少？谢谢！泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年10月30日（交易日），公司的股东户数为27,687户。感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400025412.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680707361","title":"泓博医药（301230）11月3日主力资金净卖出301.10万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680707361","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680707361?lang=zh_cn&edition=full","pubTime":"2026-11-04 09:59","pubTimestamp":1793757569,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月3日收盘，泓博医药报收于28.49元，下跌7.89%，换手率10.51%，成交量17.11万手，成交额5.02亿元。11月3日的资金流向数据方面，主力资金净流出301.1万元，占总成交额0.6%，游资资金净流入2074.82万元，占总成交额4.13%，散户资金净流出1773.72万元，占总成交额3.53%。融券方面，融券卖出500.0股，融券偿还100.0股，融券余量1.27万股，融券余额36.15万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400014323.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680749182","title":"11月3日泓博医药跌7.89%，益民红利成长混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680749182","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680749182?lang=zh_cn&edition=full","pubTime":"2026-11-03 17:24","pubTimestamp":1793697850,"startTime":"0","endTime":"0","summary":"证券之星消息，11月3日泓博医药跌7.89%，收盘报28.49元，换手率10.51%，成交量17.11万手，成交额5.02亿元。重仓泓博医药的公募基金请见下表：根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为益民基金的益民红利成长混合。益民红利成长混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300034142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680420015","title":"股市必读：泓博医药(301230)股东户数3.08万户，较上期增加18.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680420015","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680420015?lang=zh_cn&edition=full","pubTime":"2026-11-02 05:00","pubTimestamp":1793566839,"startTime":"0","endTime":"0","summary":"截至2026年10月30日收盘，泓博医药报收于29.95元，上涨0.23%，换手率15.25%，成交量24.82万手，成交额7.48亿元。股本股东变化：截至2026年10月20日股东户数为3.08万户，较9月30日增加18.7%。股本股东变化股东户数变动截至2026年10月20日公司股东户数为3.08万户，较9月30日增加4856.0户，增幅为18.7%；户均持股数量由6969.0股减少至5871.0股，户均持股市值为21.01万元。根据中登公司下发的股东名册，截至2026年10月20日（交易日），公司的股东户数为30,818户。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200001451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679215516","title":"泓博医药(301230)10月20日股东户数3.08万户，较上期增加18.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679215516","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679215516?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:29","pubTimestamp":1793359779,"startTime":"0","endTime":"0","summary":"证券之星消息，近日泓博医药披露，截至2026年10月20日公司股东户数为3.08万户，较9月30日增加4856.0户，增幅为18.7%。在医疗服务行业个股中，泓博医药股东户数低于行业平均水平，截至10月20日，医疗服务行业平均股东户数为4.99万户。从股价来看，2026年9月30日至2026年10月20日，泓博医药区间跌幅为7.02%，在此期间股东户数增加4856.0户，增幅为18.7%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000048020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679923295","title":"泓博医药：公司将充分发挥上游药物发现及工艺开发业务的项目导流优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2679923295","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679923295?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:00","pubTimestamp":1793350836,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药10月30日在投资者关系平台上答复投资者关心的问题。公司已通过优化库存结构、推进业务结构多元化等措施主动防控风险。3）公司将充分发挥上游药物发现及工艺开发业务的项目导流优势，打通从工艺开发到商业化生产的的全链条转化能力，推动研发端向生产端的自然转化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000041670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679262451","title":"泓博医药：截至2026年10月20日股东户数为30,818户","url":"https://stock-news.laohu8.com/highlight/detail?id=2679262451","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679262451?lang=zh_cn&edition=full","pubTime":"2026-10-30 15:36","pubTimestamp":1793345777,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)10月30日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好！请问截止2026年10月 20日公司的股东人数是多少？谢谢！泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年10月20日（交易日），公司的股东户数为30,818户。感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000033915.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679519422","title":"泓博医药：发挥协同优势打通全链条转化能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2679519422","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679519422?lang=zh_cn&edition=full","pubTime":"2026-10-29 15:18","pubTimestamp":1793258288,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)10月29日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司现在对商业化生产是什么战略，准备怎么改善泓博医药回复：尊敬的投资者您好！一是发挥协同优势。公司将依托上游药物发现及工艺开发业务（截至2026年9月30日占公司整体业务80%以上）的项目导流优势，打通从工艺开发到商业化生产的的全链条转化能力，推动研发端向生产端的自然转化。二是优化订单结构。优先承接创新药CDMO及CMO业务，逐步降低对单一产品的依赖，丰富收入来源。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900032912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679464449","title":"泓博医药（301230）10月28日主力资金净卖出1272.13万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679464449","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679464449?lang=zh_cn&edition=full","pubTime":"2026-10-29 09:04","pubTimestamp":1793235898,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月28日收盘，泓博医药报收于30.79元，上涨9.61%，换手率14.75%，成交量24.01万手，成交额7.19亿元。10月28日的资金流向数据方面，主力资金净流出1272.13万元，占总成交额1.77%，游资资金净流出645.47万元，占总成交额0.9%，散户资金净流入1917.6万元，占总成交额2.67%。融券方面，融券卖出3900.0股，融券偿还200.0股，融券余量1.25万股，融券余额38.46万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900015770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678122699","title":"10月27日泓博医药跌5.26%，益民红利成长混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678122699","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678122699?lang=zh_cn&edition=full","pubTime":"2026-10-27 17:09","pubTimestamp":1793092190,"startTime":"0","endTime":"0","summary":"证券之星消息，10月27日泓博医药跌5.26%，收盘报28.09元，换手率10.92%，成交量17.78万手，成交额5.16亿元。重仓泓博医药的公募基金请见下表：根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为益民基金的益民红利成长混合。益民红利成长混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700031961.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678414374","title":"泓博医药（301230）10月26日主力资金净卖出9133.30万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678414374","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678414374?lang=zh_cn&edition=full","pubTime":"2026-10-27 09:14","pubTimestamp":1793063675,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月26日收盘，泓博医药报收于29.65元，下跌8.06%，换手率17.42%，成交量28.35万手，成交额8.77亿元。10月26日的资金流向数据方面，主力资金净流出9133.3万元，占总成交额10.42%，游资资金净流入4037.78万元，占总成交额4.6%，散户资金净流入5095.51万元，占总成交额5.81%。融券方面，融券卖出0.0股，融券偿还4800.0股，融券余量6690.0股，融券余额19.84万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700011474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677970073","title":"泓博医药（301230）2026年三季报简析：增收不增利，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2677970073","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677970073?lang=zh_cn&edition=full","pubTime":"2026-10-24 06:12","pubTimestamp":1792793536,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期泓博医药发布2026年三季报。截至本报告期末，公司营业总收入5.51亿元，同比上升7.08%，归母净利润2905.07万元，同比下降16.4%。本报告期泓博医药公司应收账款体量较大，当期应收账款占最新年报归母净利润比达419.61%。本次财报公布的各项数据指标表现一般。财报体检工具显示：建议关注公司应收账款状况本文数据来源于泓博医药2026年三季报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102400005490.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677961985","title":"泓博医药（301230）披露2026年三季度报告，10月22日股价下跌6.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677961985","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677961985?lang=zh_cn&edition=full","pubTime":"2026-10-22 22:18","pubTimestamp":1792678702,"startTime":"0","endTime":"0","summary":"截至2026年10月22日收盘，泓博医药报收于34.01元，较前一交易日下跌6.77%，最新总市值为61.54亿元。该股当日开盘35.94元，最高36.63元，最低34.01元，成交额达8.23亿元，换手率为14.38%。近日，泓博医药披露《2026年三季度报告》。报告显示，2026年第三季度营业收入为186,389,395.00元，同比增长15.29%；归属于上市公司股东的净利润为321,316.27元，同比下降96.78%。年初至报告期末累计营业收入为550,795,701.14元，同比增长7.08%；归属于上市公司股东的净利润为29,050,680.01元，同比下降16.40%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200042761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677296563","title":"泓博医药：第四届董事会第十次会议决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2677296563","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677296563?lang=zh_cn&edition=full","pubTime":"2026-10-22 19:32","pubTimestamp":1792668720,"startTime":"0","endTime":"0","summary":"证券日报网讯 10月22日，泓博医药发布公告称，公司于2026年10月21日召开第四届董事会第十次会议，审议通过《关于〈2026年第三季度报告〉的议案》。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-10-22/doc-iniwcaff5212842.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-10-22/doc-iniwcaff5212842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677958292","title":"10月22日泓博医药跌6.77%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2677958292","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677958292?lang=zh_cn&edition=full","pubTime":"2026-10-22 16:53","pubTimestamp":1792659184,"startTime":"0","endTime":"0","summary":"证券之星消息，10月22日泓博医药跌6.77%，收盘报34.01元，换手率14.38%，成交量23.4万手，成交额8.23亿元。重仓泓博医药的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200028866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676091275","title":"10月19日泓博医药跌6.84%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2676091275","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676091275?lang=zh_cn&edition=full","pubTime":"2026-10-19 16:36","pubTimestamp":1792398983,"startTime":"0","endTime":"0","summary":"证券之星消息，10月19日泓博医药跌6.84%创60日新高，收盘报34.2元，换手率27.12%，成交量44.14万手，成交额16.51亿元。重仓泓博医药的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900020589.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676794915","title":"泓博医药（301230）10月16日主力资金净买入3.16亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2676794915","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676794915?lang=zh_cn&edition=full","pubTime":"2026-10-19 09:01","pubTimestamp":1792371684,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月16日收盘，泓博医药报收于36.71元，上涨14.22%，换手率24.24%，成交量39.45万手，成交额14.72亿元。10月16日的资金流向数据方面，主力资金净流入3.16亿元，占总成交额21.44%，游资资金净流出7657.85万元，占总成交额5.2%，散户资金净流出2.39亿元，占总成交额16.24%。近5日资金流向一览见下表：泓博医药融资融券信息显示，融资方面，当日融资买入2.64亿元，融资偿还8244.12万元，融资净买入1.81亿元，净买入额两市排名第3。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900002199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793939157826,"stockEarnings":[{"period":"1week","weight":0.0994},{"period":"1month","weight":-0.1463},{"period":"3month","weight":0.0133},{"period":"6month","weight":0.0034},{"period":"1year","weight":0.3055},{"period":"ytd","weight":0.4353}],"compareEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0396},{"period":"3month","weight":-0.0635},{"period":"6month","weight":-0.1172},{"period":"1year","weight":-0.0704},{"period":"ytd","weight":-0.0703}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海泓博智源医药股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"27687人(较上一季度减少10.16%)","perCapita":"5878股","listingDate":"2022-11-01","address":"上海市浦东新区庆达路315号23幢","registeredCapital":"18094万元","survey":" 上海泓博智源医药股份有限公司的主营业务是药物发现、制药工艺的研究开发以及原料药中间体的商业化生产。公司的主要产品是药物发现（CRO）、工艺研究与开发（CRO/CDMO）、商业化生产（含CMO）。","listedPrice":40},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泓博医药(301230)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泓博医药,301230,泓博医药股票,泓博医药股票老虎,泓博医药股票老虎国际,泓博医药行情,泓博医药股票行情,泓博医药股价,泓博医药股市,泓博医药股票价格,泓博医药股票交易,泓博医药股票购买,泓博医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泓博医药(301230)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}